I read with interest the article by Sinan et al entitled ''Relationship between increased serum resistin level and severity of coronary artery disease.'' 1 The authors investigated serum levels of resistin in relation to coronary artery disease (CAD) and its severity. The results revealed an elevated resistin level in patients with CAD compared to control participants with normal angiogram and a positive correlation of these levels with the severity of CAD. The authors 1 proposed that the proinflammatory activities of resistin and its role in developing insulin resistance and endothelial dysfunction may contribute to the atherogenic effects of resistin. 2 A recently discovered effect of resistin could enhance our understanding of the atherogenicity of this adipokine. Melone et al indicated that resistin treatment increases proprotein convertase subtilisin/kexin type 9 (PCSK9) via both transcriptional upregulation and posttranscriptional protein stabilization. 3 PCSK9 is a strong regulator of cholesterol homeostasis and acts via enhancement of hepatocyte low-density lipoprotein receptor (LDLR) lysosomal degradation. 4 Hence, the consequence of PCSK9 induction by resistin would be elevated serum LDL levels, an unequivocal risk factor for atherosclerotic cardiovascular disease. What is more, evidence from a knockout model has revealed that PCSK9-independent mechanisms also mediate LDLR downregulation by resistin. 3 This latter effect, being subsidiary but significant, is most probably due to the C-terminal homology between resistin and PCSK9 that enables direct interaction of resistin with the LDLR and targeting LDLR to lysosomes. 5 Since the main mechanism of action of statins is through upregulation of LDLR, PCSK9 induction by resistin may blunt the response to statins. This hypothesis was addressed by Melone et al, revealing an abrogation of statin-induced LDLR upregulation. 3 Hence, serum resistin levels in patients with CAD might have prognostic value regarding their response to statins.
In light of these observations, an explanation for the findings of Sinan et al 1 could be an attenuated response to statin therapy in patients with higher serum resistin levels, thereby causing an increased susceptibility to atherosclerosis. Further studies are required to substantiate whether elevated resistin levels are associated with a poorer response to statin therapy. Finally, large-scale clinical end point statin trials should consider post hoc analyses in order to elucidate whether the efficacy of statin therapy in reducing cardiovascular outcomes would vary between different subgroups stratified based on serum resistin levels.
